Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial
Authors:
- Nawaf YassiNYNawaf Yassi
- Henry ZhaoHZHenry Zhao
- Leonid ChurilovLCLeonid Churilov
- Bruce C V CampbellBCBruce C V Campbell
- Teddy WuTWTeddy Wu
- Henry MaHMHenry Ma
- Andrew CheungACAndrew Cheung
- Timothy KleinigTKTimothy Kleinig
- Philip ChoiPCPhilip Choi
- Jiann-Shing JengJJJiann-Shing Jeng
- Annemarei RantaARAnnemarei Ranta
Open Access
- 30 November 2021
- journal article
- research article
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 7 (2) , 158-165
Abstract
Rationale Haematoma growth is common early after intracerebral haemorrhage (ICH), and is a key determinant of outcome. Tranexamic acid, a widely available antifibrinolytic agent with an excellent safety profile, may reduce haematoma growth. Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units (STOP-MSU) is a phase II double-blind, randomised, placebo-controlled, multicentre, international investigator-led clinical trial, conducted within the estimand statistical framework. Hypothesis In patients with spontaneous ICH, treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo. Sample size estimates A sample size of 180 patients (90 in each arm) would be required to detect an absolute difference in the primary outcome of 20% (placebo 39% vs treatment 19%) under a two-tailed significance level of 0.05. An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients. Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min, followed by 1 g intravenous tranexamic acid over 8 hours; or matching placebo. Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours, defined as either ≥33% relative increase or ≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan. Discussion We describe the rationale and protocol of STOP-MSU, a phase II trial of tranexamic acid in patients with ICH within 2 hours from onset, based in participating mobile stroke units and emergency departments.Keywords
Funding Information
- Medical Research Future Fund, Australia (APP1152282)
This publication has 28 references indexed in Scilit:
- An Improved Method for Simple, Assumption-Free Ordinal Analysis of the Modified Rankin Scale Using Generalized Odds RatiosInternational Journal of Stroke, 2014
- Stroke Unit Care Benefits Patients With Intracerebral HemorrhageStroke, 2013
- Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhageCochrane Database of Systematic Reviews, 2013
- Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral HemorrhageNew England Journal of Medicine, 2013
- Strategy for intention to treat analysis in randomised trials with missing outcome dataBMJ, 2011
- Guidelines for the Management of Spontaneous Intracerebral HemorrhageStroke, 2010
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialThe Lancet, 2010
- Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral HemorrhageNew England Journal of Medicine, 2008
- Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhageNeurology, 2006
- Recombinant Activated Factor VII for Acute Intracerebral HemorrhageNew England Journal of Medicine, 2005